Literature DB >> 6228536

Suppressor cells in levamisole-treated mice: a possible role of T-cell-mediated feedback suppression in the drug-induced suppression of the humoral immune response.

S Kurakata, K Kitamura.   

Abstract

The suppressive effect of levamisole (LMS) on the primary IgM plaque-forming cell (PFC) response to sheep erythrocytes in mice was studied. The suppressive effect of LMS on day 4 PFC response was found to be modified by dose, the timing of drug administration, and the amount of antigen injected. The experiments, using an inhibitory dose of 10 mg/kg LMS, showed that: 1) T cells play an essential role in LMS-induced suppression; 2) antigen-specific suppressor cells are induced in the spleen of LMS-treated mice; 3) the spleen cells from LMS-treated donors either suppress or enhance the PFC response in the recipients, depending on the amount of antigen injected and the number of spleen cells transferred; and 4) a dose of 10 mg/kg LMS, which is inhibitory when assessed on day 4 PFC response, actually enhances the response three and a half days after the immunization. These results suggest that LMS induces precursors of both helper and suppressor cells, and their differentiation and/or maturation to LMS-primed antigen-specific suppressor T cells are modulated, at least in part, by T-cell-mediated feedback suppression.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6228536     DOI: 10.1016/0162-3109(83)90034-6

Source DB:  PubMed          Journal:  Immunopharmacology        ISSN: 0162-3109


  4 in total

1.  Immunomodulation therapy in children with chronic hepatitis B.

Authors:  Murat Karaoglan; Fikret Demirci; Yavuz Coskun; Ilkay Karaoglan; Ziya Bayraktaroglu; Vahap Okan; Tekin Karsligil
Journal:  J Natl Med Assoc       Date:  2006-02       Impact factor: 1.798

2.  Effect of levamisole on the immune response of patients with schistosomiasis after treatment with praziquantel.

Authors:  J R Snyman; de K Sommers
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

3.  Modulation of the immune response to tumors by a novel synthetic compound, (4R)-3-benzoyl-N-[(1R)-1-phenylethyl]-4-thiazolidinecarboxamide (RS-0481).

Authors:  S Kurakata; M Tomatsu; M Arai; H Arai; A Hishinuma; H Kohno; K Kitamura; T Kobayashi; K Nomoto
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

4.  Levamisole Suppresses CD4+ T-Cell Proliferation and Antigen-Presenting Cell Activation in Aplastic Anemia by Regulating the JAK/STAT and TLR Signaling Pathways.

Authors:  Jiali Wang; Jia Liu; Mingyang Wang; Fei Zhao; Meili Ge; Li Liu; Erlie Jiang; Sizhou Feng; Mingzhe Han; Xiaolei Pei; Yizhou Zheng
Journal:  Front Immunol       Date:  2022-07-14       Impact factor: 8.786

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.